聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 52 分钟 55 秒 前

Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness

周一, 01/13/2014 - 16:36
Terms include $125 million upfront payment in cash plus a potential of up to $272 million in milestone payments Investor conference call to be held today, January 13 at 8:30 AM EST/1:30 PM GMT DUBLIN, Jan. 13, 2014 -- (Healthcare Sales & Marketing Ne...
Biopharmaceuticals, Acquisitions
Jazz Pharmaceuticals, Aerial Biopharma, daytime sleepiness

Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as Director

周一, 01/13/2014 - 16:30
PLYMOUTH, Mich.--(Healthcare Sales & Marketing Network)--Esperion Therapeutics, Inc. (ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering the...
Biopharmaceuticals, Cardiology, Personnel
Esperion Therapeutics, hypercholesterolemia

Cardica Appoints Industry Veteran Liam Burns As Vice President, Sales And Marketing

周一, 01/13/2014 - 16:28
REDWOOD CITY, Calif., Jan. 13, 2014 -- (Healthcare Sales & Marketing Network) -- Cardica, Inc. (CRDC) today announced it has appointed Liam Burns to the position of Vice President, Sales and Marketing. "Liam has been working with Cardica for sever...
Devices, Surgery, Personnel
Cardica, MicroCutter, XCHANGE 30, surgical stapling

Mallinckrodt Pharmaceuticals and Medtronic Announce Clinical and Commercial Collaboration

周一, 01/13/2014 - 16:25
Collaboration agreement will focus on furthering pre-clinical, clinical and commercial aspects of intrathecal therapeutics ST. LOUIS, Mo.--(Healthcare Sales & Marketing Network)--Mallinckrodt (MNK) announced today that it has entered into a multiyear ag...
Biopharmaceuticals, Devices, Drug Delivery, Neurology
Mallinckrodt, Medtronic, SynchroMed, intrathecal

BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A

周一, 01/13/2014 - 16:21
SAN RAFAEL, Calif., Jan. 13, 2014 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (BMRN) announced today that it has selected an AAV-factor VIII vector, BMN 270, to develop for the treatment of hemophilia A and has initiated IND-e...
Biopharmaceuticals
BioMarin Pharmaceutical, Factor VIII, Hemophilia

Alcobra Strengthens Management Team With Addition of Industry Veteran David C. Baker as Chief Commercial Officer

周一, 01/13/2014 - 16:19
Led Efforts to Build Shire's Pipeline of ADHD and CNS Products Launched Vyvanse(R), the #1 ADHD Brand in the U.S. Brand management experience on five different billion dollar brands across three therapeutic categories TEL AVIV, Israel, Jan. 13, 20...
Biopharmaceuticals, Neurology, Personnel
Alcobra, Metadoxine, cognitive dysfunction, ADHD

Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis

周一, 01/13/2014 - 16:15
Portola to Receive Upfront and Milestone Payments While Retaining Full Worldwide Rights to Andexanet Alfa SOUTH SAN FRANCISCO, Calif., Jan. 13, 2014 -- (Healthcare Sales & Marketing Network) -- Portola Pharmaceuticals (PTLA) today announced that it has ...
Biopharmaceuticals
Portola Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Factor Xa, Eliquis

Galena Biopharma Acquires Mills Pharmaceuticals, LLC

周一, 01/13/2014 - 16:10
Acquisition adds GALE-401 (Anagrelide CR) to expand Galena's product pipeline. Phase 2 clinical trial expected to begin in mid-2014 with GALE-401 to treat Essential Thrombocythemia (ET), an orphan myeloproliferative disorder. PORTLAND, Ore., Jan. 13,...
Biopharmaceuticals, Mergers & Acquisitions
Galena Biopharma, Mills Pharmaceuticals, Anagrelide, Thrombocythemia

Agenus Appoints Robert B. Stein, MD, PhD, as Chief Scientific Officer

周一, 01/13/2014 - 16:06
LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--Agenus Inc. (AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced the appointment of Robert B. Stein, M.D., Ph.D.,...
Biopharmaceuticals, Oncology, Personnel
Agenus

Integrity Applications Signs Distribution Agreement for GlucoTrack(R) Model DF-F Glucose Monitoring Device

周一, 01/13/2014 - 16:04
ASHKELON, Israel--(Healthcare Sales & Marketing Network)--Integrity Applications, Inc. (IGAP), developer of the GlucoTrack® model DF-F non-invasive blood glucose measurement device, has entered into a distribution agreement appointing Ultramedix Austra...
Devices, Monitoring, Endocrinology, Distribution
Integrity Applications, GlucoTrack, blood glucose

Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG

周一, 01/13/2014 - 16:02
Antibody has a powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets Lead programs target six immune checkpoint molecules Checkpoint antibodies have produced unprecedented results a...
Biopharmaceuticals, Oncology, Mergers & Acquisitions
Agenus, 4-Antibody AG, Retrocyte Display

Insys Announces Details of Product Development Pipeline

周一, 01/13/2014 - 15:57
PHOENIX, AZ--(Healthcare Sales & Marketing Network) - Insys Therapeutics, Inc. (NASDAQ: INSY) today unveiled details of its portfolio pipeline, focused on innovative supportive care and therapy products. The Company intends to file one New Drug Application...
Biopharmaceuticals, Drug Delivery
Insys Therapeutics, sublingual fentanyl, Dronabinol

Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics

周一, 01/13/2014 - 13:08
INDIANAPOLIS, Jan. 13, 2014 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) today announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody current...
Biopharmaceuticals, Acquisitions
Eli Lilly, Arteaus Therapeutics, CGRP Antibody, migraine

EndoChoice Adds Board Members

周一, 01/13/2014 - 12:53
CEOs of UPS and Volcano Corporation Will Help Guide Growth Plans ATLANTA, Jan. 13, 2014 -- (Healthcare Sales & Marketing Network) -- EndoChoice® has added two highly regarded business leaders to the board of directors. Mr. Scott Davis, the Chairma...
Devices, Personnel
EndoChoice, endoscopy, Fuse, Full Spectrum Endoscopy

U.S. FDA Approves Farxiga(TM) (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes

周一, 01/13/2014 - 12:43
In clinical trials, new once-daily Farxiga, in addition to diet and exercise, improved glycemic control by removing glucose from the body WILMINGTON, Del. & PRINCETON, N.J.--(Healthcare Sales & Marketing Network)--AstraZeneca (AZN) and Bristol-Myers Squ...
Biopharmaceuticals, Endocrinology, FDA
AstraZeneca, Bristol-Myers Squibb, Farxiga, dapagliflozin, diabetes

Incyte Names Hervé Hoppenot President and Chief Executive Officer

周一, 01/13/2014 - 12:36
Former President of Novartis Oncology to Lead Incyte’s Future Growth WILMINGTON, Del.--(Healthcare Sales & Marketing Network)--Incyte Corporation (INCY) announced today that Hervé Hoppenot, former President of Novartis Oncology, has been named Pr...
Biopharmaceuticals, Oncology, Personnel
Incyte

A.P. Pharma Announces Appointment of New Directors and Effective Date of Name Change and Reverse Stock Split

周一, 01/13/2014 - 12:25
Reverse split implemented in support of NASDAQ listing application REDWOOD CITY, Calif.--(Healthcare Sales & Marketing Network)--A.P. Pharma, Inc. (APPA), a specialty pharmaceutical company, today announced that it has changed its name to Heron Therapeu...
Biopharmaceuticals, Drug Delivery, Personnel
A.P. Pharma, Heron Therapeutics, Biochronomer

Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases

周一, 01/13/2014 - 05:02
Genzyme to Obtain Significant Global Rights to Alnylam's Pipeline Alnylam Retains Most Product Rights in North America and Western Europe Genzyme Becomes Major Alnylam Shareholder through $700 Million Equity Investment PARIS and CAMBRIDGE, Mass., ...
Biopharmaceuticals, Licensing
Genzyme, Sanofi, Alnylam Pharmaceuticals, RNAi therapeutics, genetic medicines

Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines

周一, 01/13/2014 - 05:01
New Collaboration Expected to Accelerate and Expand Global Product Value for RNAi Therapeutic Genetic Medicine Pipeline, Including “Alnylam 5x15” Programs Alnylam Retains Broad Product Rights in North America and Western Europe and Genzyme Obtains Right...
Biopharmaceuticals, Licensing
Alnylam Pharmaceuticals, Genzyme, Sanofi, RNAi therapeutics, genetic medicines

OvaScience Announces Global Healthcare Strategist Marc Kozin Joins Company’s Board of Directors

周五, 01/10/2014 - 14:56
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--OvaScienceSM, (OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Marc Kozin, former Pre...
Biopharmaceuticals, Personnel
OvaScience, EggPC, OvaTure, infertility, in vitro fertilization

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong